ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Immune-Mediated Injury in Kidney Transplant Recipients Treated With Alemtuzumab Induction and a Steroid Avoidance Protocol

R. Sapir-Pichhadze, T. Mahbub, C. Saw, D. Baran.

McGill University Health Centre, Montreal, Canada.

Meeting: 2015 American Transplant Congress

Abstract number: A149

Keywords: Antibodies, Induction therapy, Rejection, Renal failure

Session Information

Session Name: Poster Session A: Kidney Immunosuppression: Induction Therapy

Session Type: Poster Session

Date: Saturday, May 2, 2015

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Exhibit Hall E

Study purpose: We evaluated short-term clinical and immunological outcomes of kidney transplant recipients who received alemtuzumab induction and a steroid-avoidance protocol.

Methods: This is a retrospective cohort study including all adult first kidney transplant recipients who underwent transplantation at McGill University Health Centre Sept 2011 to Dec 2013. These CDC crossmatch negative patients were induced with alemtuzumab 30 mg and 500 mg of methylprednisolone, followed by dual-agent maintenance therapy with tacrolimus and mycophenolate mofetil. This regimen replaced a previous protocol using thymoglobulin induction and triple maintenance therapy with a calcineurin inhibitor, mycophenolate mofetil, and low-dose prednisone. Prospective screening for donor specific antibodies (DSA) using solid phase assays was conducted at 1-, 3-, 6-, 12-months and annually thereafter. Study endpoints were time to DSA development, biopsy-proven rejection and graft failure. Antibody-mediated rejection (AMR) was treated with plasmapheresis, IvIg, and rituximab.

Results: Of 107 eligible patients, 14 (13.1%) developed DSA within a median of 6 months (interquartile range: 2, 7). Nine (8.4%) developed de novo DSA and 5 (4.7%) without DSA at transplantation had recurrence of historical DSA. Class I, class II and both class I and class II DSA were identified in 5 (35.7%), 5 (35.7%) and 4 (28.6%) of DSA+ patients, respectively. Among DSA- patients, 36 had at least 1 allograft biopsy (12/36 surveillance; 24/36 for cause). DSA+ patients mainly underwent biopsies for-cause (10/14 or 71.4%) and all were diagnosed with AMR/TG. TG alone appeared in 5/93 (5.3%) DSA- patients. Five (35.7%) DSA+ patients experienced cellular rejection prior to (2 patients) or concurrently with AMG/TR (3 patients). Cellular rejection occurred in 9.6% of DSA- patients. Non-adherence, medication errors, and physician-initiated dosage reduction preceded DSA appearance. To date, 3 DSA+ patients (21.4%) and only 1 (1.1%) DSA- patient experienced allograft failure.

Conclusion: Incidence of cellular rejection remained low following the implementation of an alemtuzumab induction and a steroid-avoidance protocol. Greater pre-transplant immunological risk (i.e. documented historical DSA) and/or under-immunosuppression often preceded DSA appearance. Excess allograft failure in DSA+ patients underscores the importance of medication adherence and adequate drug dosing for the prevention of allograft loss.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Sapir-Pichhadze R, Mahbub T, Saw C, Baran D. Immune-Mediated Injury in Kidney Transplant Recipients Treated With Alemtuzumab Induction and a Steroid Avoidance Protocol [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/immune-mediated-injury-in-kidney-transplant-recipients-treated-with-alemtuzumab-induction-and-a-steroid-avoidance-protocol/. Accessed May 9, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences